References
- Ambrosini G, Adida C, Altieri DC. (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–21.
- Andreoli MCC, Dalboni MA, Watanabe R, et al. (2007). Impact of dialyzer membrane on apoptosis and function of polymorphonuclear cells and cytokine synthesis by peripheral blood mononuclear cells in hemodialysis patients. Artif Organs 31:887–910.
- Bootcov MR, Bauskin AR, Valenzuela SM, et al. (1997). MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 94:11514–19.
- Breit SN, Carrero JJ, Tsai VW, et al. (2012). Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant 27:70–5.
- Cassis P, Solini S, Azzollini N, et al. (2014). An unanticipated role for survivin in organ transplant damage. Am J Transplant 14:1046–60.
- Chen J, Chen JK, Conway EM, Harris RC. (2013). Survivin mediates renal proximal tubule recovery from AKI. J Am Soc Nephrol 24:2023–33.
- Corre J, Hebraud B, Bourin P. (2013). Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med 2:946–52.
- Daniels LB, Clopton P, Laughlin GA, et al. (2011). Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation 123:2101–10.
- Faull RJ, Stanley JM, Fraser S, et al. (2001). HB-EGF is produced in the peritoneal cavity and enhances mesothelial cell adhesion and migration. Kidney Int 59:614–24.
- Grandaliano G, Gesualdo L, Bartoli F, et al. (2000). MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy. Kidney Int 58:182–92.
- Iwamoto I, Imada A. (1992). Effects of growth factors on proliferation of cultured human peritoneal mesothelial cells. Nihon Jinzo Gakkai Shi 34:1201–8.
- Johnen H, Lin S, Kuffner T, et al. (2007). Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 13:1333–40.
- Ku JH, Godoy G, Amiel GE, Lerner SP. (2012). Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review. BJU Int 110:630–6.
- Lurbe E, Cifkova R, Cruickshank JK, et al. (2009). Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 27:1719–42.
- Musiał K, Bargenda A, Zwolińska D. (2015). Urine survivin, E-cadherin and matrix metalloproteinases as novel biomarkers in children with chronic kidney disease. Biomarkers 20:177–82.
- Sertic J, Slavicek J, Bozina N, et al. (2007). Cytokines and growth factors in mostly atherosclerotic patients on hemodialysis determined by biochip array technology. Clin Chem Lab Med 45:1347–52.
- Stangou M, Alexopoulos E, Papagianni A, et al. (2009). Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrology (Carlton) 14:613–20.
- Tang J, Liu N, Zhuang S. (2013). Role of epidermal growth factor receptor in acute and chronic kidney injury. Kidney Int 83:804–10.
- Torres DD, Rossini M, Manno C, et al. (2008). The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int 73:327–33.
- Waligórska-Stachura J, Jankowska A, Waśko R, et al. (2012). Survivin-prognostic tumor biomarker in human neoplasms-review. Ginekol Pol 83:537–40.
- Wiklund FE, Bennet AM, Magnusson PK, et al. (2010). Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 9:1057–64.
- Xu X, Li Z, Gao W. (2011). Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside. Biomarkers 16:466–75.
- Yilmaz H, Çelik HT, Gurel OM, et al. (2015). Increased serum levels of GDF-15 associated with mortality and subclinical atherosclerosis in patients on maintenance hemodialysis. Herz 40:305–12.